Company intelligence / Profile preview
SQ Innovation, Inc.
Zug, Zug, Switzerlandsqinnovation.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- NDA
01
Overview
Lasix ONYU, a novel high-concentration furosemide formulation delivered via an on-body infusor device for at-home treatment of fluid overload in chronic heart failure patients, received Tentative FDA Approval in late 2024. Full approval and commercial launch are expected after the expiration of exclusivity for a competing product.[6][8] Clinical results indicate comparable efficacy to IV administration with the benefit of at-home use.
- Therapeutic areas
- OtherCardiovascular
- Modalities
- Small molecules (furosemide/Lasix)Drug-device combination products
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Gerresheimer AG – design/manufacturing partner for the on-body drug delivery device used with Lasix ONYU
Beyond the preview
Go deeper on SQ Innovation, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SQ Innovation, Inc..